293 related articles for article (PubMed ID: 24709976)
1. Emerging new anticancer therapies in 2013.
Gomez-Roca C; Delord JP
Curr Opin Oncol; 2014 May; 26(3):357-62. PubMed ID: 24709976
[TBL] [Abstract][Full Text] [Related]
2. [Hot topics about early clinical trials at ASCO congress 2018: News pathways, new targets, new associations].
Auvray M; Baylot C; Blanc-Durand F; Borcoman E; Pons-Tostivint E; Vignot S
Bull Cancer; 2018 Nov; 105(11):1084-1093. PubMed ID: 30340752
[TBL] [Abstract][Full Text] [Related]
3. [ESMO ECCO 2015: The highlights of immunotherapy and targeted therapies].
Bonnet C; Beinse G; Cabel L; Cochereau D; Lavaud P; Rochefort P; Tabouret E; Turpin A; Verlingue L; Vicier C; Massard C
Bull Cancer; 2016 Jun; 103(6):594-603. PubMed ID: 27229364
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
5. Emerging new anticancer biological therapies in 2013 (haematological malignancies).
Plawny L; Ries F
Curr Opin Oncol; 2014 May; 26(3):363-70. PubMed ID: 24663027
[TBL] [Abstract][Full Text] [Related]
6. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
7. What is new in kidney cancer?
Kirkali Z
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1753-5. PubMed ID: 19954286
[TBL] [Abstract][Full Text] [Related]
8. An update on clinical trials of targeted therapies in thyroid cancer.
Haraldsdottir S; Shah MH
Curr Opin Oncol; 2014 Jan; 26(1):36-44. PubMed ID: 24240178
[TBL] [Abstract][Full Text] [Related]
9. Molecular targets in cancer therapy.
Kummar S; Doroshow JH
Expert Rev Anticancer Ther; 2013 Mar; 13(3):267-9. PubMed ID: 23477512
[TBL] [Abstract][Full Text] [Related]
10. American Society of Clinical Oncology 41st annual meeting.
Dillman RO
Expert Opin Biol Ther; 2005 Aug; 5(8):1117-27. PubMed ID: 16050788
[TBL] [Abstract][Full Text] [Related]
11. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Gralow J; Ozols RF; Bajorin DF; Cheson BD; Sandler HM; Winer EP; Bonner J; Demetri GD; Curran W; Ganz PA; Kramer BS; Kris MG; Markman M; Mayer RJ; Raghavan D; Ramsey S; Reaman GH; Sawaya R; Schuchter LM; Sweetenham JW; Vahdat LT; Davidson NE; Schilsky RL; Lichter AS;
J Clin Oncol; 2008 Jan; 26(2):313-25. PubMed ID: 18086794
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy and targeted therapy for cervical cancer: an update.
Menderes G; Black J; Schwab CL; Santin AD
Expert Rev Anticancer Ther; 2016; 16(1):83-98. PubMed ID: 26568261
[TBL] [Abstract][Full Text] [Related]
13. Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer.
Albo D; Farrow B; Berger DH
Surg Oncol Clin N Am; 2008 Apr; 17(2):357-76, ix. PubMed ID: 18375357
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic consequences of molecular biology advances in oncology].
Bauvet F; Awada A; Gil T; Hendlisz A
Bull Cancer; 2009 Jan; 96(1):59-71. PubMed ID: 19211361
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics.
Miller MJ; Foy KC; Kaumaya PT
Discov Med; 2013 Mar; 15(82):166-76. PubMed ID: 23545045
[TBL] [Abstract][Full Text] [Related]
16. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Ozols RF; Herbst RS; Colson YL; Gralow J; Bonner J; Curran WJ; Eisenberg BL; Ganz PA; Kramer BS; Kris MG; Markman M; Mayer RJ; Raghavan D; Reaman GH; Sawaya R; Schilsky RL; Schuchter LM; Sweetenham JW; Vahdat LT; Winn RJ;
J Clin Oncol; 2007 Jan; 25(1):146-62. PubMed ID: 17158528
[TBL] [Abstract][Full Text] [Related]
17. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli K; Stelloo E; Peters GJ; VAN DEN Eertwegh AJ
Anticancer Res; 2014 Apr; 34(4):1493-505. PubMed ID: 24692676
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy Advances: 2019.
Saleh N
Oncology (Williston Park); 2019 Oct; 33(10):. PubMed ID: 31661150
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib for the treatment of renal cancer.
Al-Marrawi MY; Rini B
Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
[TBL] [Abstract][Full Text] [Related]
20. [New drugs and targeted therapeutic agents in ovarian cancer].
de La Motte Rouge T; Petrella MC; Michels J; Even C; Balleyguier C; Duclos J; Mazeron R; Morice P; Pautier P; Lhommé C
Bull Cancer; 2009 Dec; 96(12):1215-24. PubMed ID: 19919916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
